Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates - Sorbonne Université
Journal Articles Nature Communications Year : 2021

Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates

Natalie Daniele
  • Function : Author
Bernard Gjata
  • Function : Author
Jeremie Cosette
  • Function : Author

Abstract

Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with enzyme replacement therapy (ERT) with intravenous infusions of recombinant human GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the management of PD, the approach suffers from several shortcomings. Here, we developed a mouse model of PD to compare the efficacy of hepatic gene transfer with adeno-associated virus (AAV) vectors expressing secretable GAA with long-term ERT. Liver expression of GAA results in enhanced pharmacokinetics and uptake of the enzyme in peripheral tissues compared to ERT. Combination of gene transfer with pharmacological chaperones boosts GAA bioavailability, resulting in improved rescue of the PD phenotype. Scale-up of hepatic gene transfer to non-human primates also successfully results in enzyme secretion in blood and uptake in key target tissues, supporting the ongoing clinical translation of the approach.
Fichier principal
Vignette du fichier
s41467-021-26744-4.pdf (4.05 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03449262 , version 1 (25-11-2021)

Licence

Identifiers

Cite

Helena Costa-Verdera, Fanny Collaud, Christopher R Riling, Pauline Sellier, Jayme M L Nordin, et al.. Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates. Nature Communications, 2021, 12 (1), pp.6393. ⟨10.1038/s41467-021-26744-4⟩. ⟨hal-03449262⟩
74 View
44 Download

Altmetric

Share

More